Processed B-type natriuretic peptide is a biomarker of postinterventional restenosis in ischemic heart disease

Clinical Chemistry

Volumn 59, Issue 9, 2013, Pages 1330-1337

  Fujimoto, Hirotaka ^a,b   Suzuki, Toru ^a,c   Aizawa, Kenichi ^a   Sawaki, Daigo ^a,c   Ishida, Junichi ^a   Ando, Jiro ^a   Fujita, Hideo ^a   Komuro, Issei ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c SHIMADZU CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; IMMUNOCAPTURE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RESTENOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

AGED; CORONARY RESTENOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN;

EID: 84883337186     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.203406     Document Type: Article

References (40)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
2. Butany J, Carmichael K, Leong SW, Collins MJ. Coronary artery stents: identification and evaluation. J Clin Pathol 2005;58:795-804.
3. Jukema JW, Verschuren JJ, Ahmed TA, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol 2012;9:53-62.
4. Agema WR, Monraats PS, Zwinderman AH, De Winter RJ, Tio RA, Doevendans PA, et al. Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drugeluting stent era. Eur Heart J 2004;25:1163-70.
5. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol 2010;56:S1- 42.
6. Stolker JM, Kennedy KF, Lindsey JB, Marso SP, Pencina MJ, Cutlip DE, et al. Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry. Circ Cardiovasc Interv 2010;3:327-34.
7. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
8. Suzuki T, Yamazaki T, Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res 2001;51:489-94.
9. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-7.
10. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of car- diac natriuretic peptides: a review. Clin Chem 2004;50:33-50.
11. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-72.
12. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004; 44:1988-95.
13. Goetze JP. B-type natriuretic peptide: from posttranslational processing to clinical measurement. Clin Chem 2012;58:83-91.
14. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, De Meester I. Dipeptidylpeptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006; 52:82-7.
15. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008;1:258-64.
16. Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, Serebryanaya DV, et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem 2010; 56:1166-76.
17. Van Eyk JE, Powers F, Law W, Larue C, Hodges RS, Solaro RJ. Breakdown and release of myofilament proteins during ischemia and ischemia/ reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. Circ Res 1998;82:261-71.
18. McDonough JL, Labugger R, Pickett W, Tse MY, MacKenzie S, Pang SC, et al. Cardiac troponin I is modified in the myocardium of bypass patients. Circulation 2001;103:58-64.
19. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011;3:77sr1.
20. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011;305:261-6.
21. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.
22. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003;12:87-100.
23. Holst JJ. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv Exp Med Biol 2003;524:263-79.
24. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, III, Loop FD, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988;78:486-502.
25. Ishida J, Suzuki T, Aizawa K, Sawaki D, Nagai R. Comparison of analytical performance of two single-step measurement devices of B-type natriuretic peptide. Int Heart J 2012;53:320-3.
26. Kono M, Yamauchi A, Tsuji T, Misaka A, Igano K, Ueki K, et al. An immunoradiometric assay for brain natriuretic peptide in human plasma. Jpn Soc Nuc Med Tech 1993;13:2-7.
27. Suzuki T, Distante A, Zizza A, Trimarchi S, Villani M, Salerno Uriarte JA, et al. Diagnosis of acute aortic dissection by D-dimer: the International Registry of Acute Aortic Dissection Substudy on Biomarkers (IRAD-Bio) experience. Circulation 2009;119:2702-7.
28. Ichiki T, Huntley BK, Heublein DM, Sandberg SM, McKie PM, Martin FL, et al. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin Chem 2011;57:40-7.
29. Peng J, Jiang J, Wang W, Qi X, Sun XL, Wu Q. Glycosylation and processing of pro-B-type natriuretic peptide in cardiomyocytes. Biochem Biophys Res Commun 2011;411:593-8.
30. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993; 291:83-8.
31. Semenov AG, Seferian KR, Tamm NN, Artem'eva MM, Postnikov AB, Bereznikova AV, et al. Human pro-B-type natriuretic peptide is processed in the circulation in a rat model. Clin Chem 2011;57: 883-90.
32. Suzuki T, Ishiwata S, Hasegawa K, Yamamoto K, Yamazaki T. Raised interleukin 6 concentrations as a predictor of postangioplasty restenosis. Heart 2000;83:578.
33. Suzuki T, Kohno H, Hasegawa A, Toshima S, Amaki T, Kurabayashi M, et al. Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease. Clin Biochem 2002;35: 347-53.
34. Shigematsu S, Takahashi N, Hara M, Yoshimatsu H, Saikawa T. Increased incidence of coronary in-stent restenosis in type 2 diabetic patients is related to elevated serum malondialdehydemodified low-density lipoprotein. Circ J 2007;71: 1697-702.
35. Cooke T, Sheahan R, Foley D, Reilly M, D'Arcy G, Jauch W, et al. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation 1994;89: 1593-8.
36. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
37. Hahn JY, Kim HS, Koo BK, Na SH, Chung JW, Youn TJ, et al. One month follow-up C-reactive protein may be a useful predictor of angiographic restenosis and long-term clinical outcomes after bare metal stent implantation. Int J Cardiol 2006; 109:267-9.
38. Park DW, Lee CW, Yun SC, Kim YH, Hong MK, Kim JJ, et al. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drugeluting stent implantation. Heart 2007;93:1087-92.
39. Moldoveanu E, Mut-Vitcu B, Tanaseanu GR, Marta DS, Manea G, Kosaka T, et al. Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase. Clin Biochem 2008;41:1429-33.
40. Farooq V, Gogas BD, Serruys PW. Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv 2011;4: 195-205.